Investors & Media

Press Releases

Official announcements and clinical milestones from Eloxx Pharmaceuticals.

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

Read press release →

Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors

Read press release →

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Read press release →

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Read press release →

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq

Read press release →

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Read press release →

Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

Read press release →

Almirall and Eloxx Pharmaceuticals Enter Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases

Read press release →

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Read press release →

Exaluren Induces COL4A5 Readthrough Across 49 Nonsense Variants in Alport Syndrome

Read publication →